Akebia Therapeutics (AKBA) vs BGM Group (BGM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Akebia Therapeutics (AKBA) has outperformed BGM Group (BGM) over the past year, losing 75.1% versus a loss of 96.7%. Over five years, AKBA leads with a -85.6% price change compared with -98.3% for BGM. BGM Group is the larger company by market cap ($108.6 million vs $107.0 million), about 1.0 times the size.
Akebia Therapeutics converts more of its revenue into profit, with a net margin of -2.3% versus -52.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | BGM |
|---|---|---|
| Share price | $0.3855 | $8.13 |
| Market cap | $107.04M | $108.57M |
| 1-day change | -8.71% | 0.00% |
| YTD return | -76.06% | -92.77% |
| 1-year return | -75.13% | -96.73% |
| 5-year return | -85.56% | -98.31% |
| EPS (TTM) | $-0.17 | $-4.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | $37.92M |
| Revenue growth (YoY) | +47.46% | +51.09% |
| Net income (latest FY) | $-5.34M | $-19.94M |
| Gross margin | 83.29% | 16.64% |
| Operating margin | 9.95% | -33.18% |
| Net margin | -2.26% | -52.59% |
| 52-week high | $1.73 | $263.70 |
| 52-week low | $0.361 | $0.00 |
| Distance from 52-week high | -77.72% | -96.92% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +678.21% | — |
| Average volume | 8.05M | 6.18K |
| Shares outstanding | 277.66M | 12.69M |
| Employees | 194 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKBA has outperformed BGM by 21.6 percentage points over the past year.
- Akebia Therapeutics is more profitable, keeping -2.3 cents of every revenue dollar as net income versus -52.6 cents for BGM Group.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
AKBA vs BGM FAQ
Which is bigger, Akebia Therapeutics or BGM Group?
BGM Group (BGM) is larger, with a market capitalization of $108.57M compared with $107.04M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or BGM?
AKBA returned -75.13% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and BGM Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.